Document Detail


In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review.
MedLine Citation:
PMID:  25042751     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Fetal congenital cystic adenomatoid malformation (CCAM) can progress to nonimmune hydrops, and the mortality rate of CCAM with hydrops is reported to be nearly 100%. We describe three microcystic CCAM cases in which the fetal condition improved after maternal betamethasone therapy. The median gestational age at steroid administration was 23 5/7 weeks' gestation. The CCAM decreased in size in all cases. Our series showed a 100% hydrops resolution rate (2/2) and a 100% survival rate (3/3). Our experience suggests the efficacy of betamethasone treatment on fetuses with microcystic CCAM who have fluid collection or are at risk of developing hydrops. © 2014 Wiley Periodicals, Inc. J Clin Ultrasound, 2014.
Authors:
Akiko Yamashita; Nobuhiro Hidaka; Ryo Yamamoto; Soichiro Nakayama; Jun Sasahara; Keisuke Ishii; Nobuaki Mitsuda
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-7-15
Journal Detail:
Title:  Journal of clinical ultrasound : JCU     Volume:  -     ISSN:  1097-0096     ISO Abbreviation:  J Clin Ultrasound     Publication Date:  2014 Jul 
Date Detail:
Created Date:  2014-7-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401663     Medline TA:  J Clin Ultrasound     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014 Wiley Periodicals, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Understanding perceptions of stuttering among school-based speech-language pathologists: An applicat...
Next Document:  How to unfasten the Spanish Stroke Belt? Andalusia chooses research.